Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Executive VP Global Operations | March 05, 2024 | March 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date March 05, 2024 · Filed March 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 145,915 |
Last balance in matching sequence
After 2024-03-05 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-03-05 · Exercise / conversion · Acquired 22,576 · Balance 90,689 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Amount reflects the sale of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on March 1, 2024, which was inadvertently omitted from the amount of securities beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024. Row 2 · 2024-03-05 · Exercise / conversion · Acquired 55,226 · Balance 145,915 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Amount reflects the sale of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on March 1, 2024, which was inadvertently omitted from the amount of securities beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 22,576 |
Reported balance
After 2024-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-05 · Exercise / conversion · Disposed 22,576 · Balance 22,576 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4: Restricted share units were granted on March 5, 2021, with 22,576 vested on March 5, 2022, March 5, 2023, March 5, 2024 and 22,576 vesting on March 5, 2025. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-05 · Exercise / conversion · Disposed 55,226 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Amount reflects the sale of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on March 1, 2024, which was inadvertently omitted from the amount of securities beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024.
F4: Restricted share units were granted on March 5, 2021, with 22,576 vested on March 5, 2022, March 5, 2023, March 5, 2024 and 22,576 vesting on March 5, 2025.
F5: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2024 Filed Mar 7, 2024 16:24 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 55,226 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-028002 · ownership.xml · derivative · entry 4 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 55,226 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024. F5 · derivative.expiration_date: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:24 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 22,576 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-028002 · ownership.xml · derivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,576 Underlying: Ordinary Shares · 22,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 vested on March 5, 2022, March 5, 2023, March 5, 2024 and 22,576 vesting on March 5, 2025. F4 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 vested on March 5, 2022, March 5, 2023, March 5, 2024 and 22,576 vesting on March 5, 2025. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:24 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 55,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-028002 · ownership.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · balance_after: Amount reflects the sale of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on March 1, 2024, which was inadvertently omitted from the amount of securities beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:24 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 22,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-028002 · ownership.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · balance_after: Amount reflects the sale of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on March 1, 2024, which was inadvertently omitted from the amount of securities beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 16:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 33,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025995 · ownership.xml · derivative · entry 4 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,024 Underlying: Ordinary Shares · 33,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 16:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 33,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025995 · ownership.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 16:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 24,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025995 · ownership.xml · derivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,701 Underlying: Ordinary Shares · 24,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 16:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 24,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025995 · ownership.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 06:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 19,515 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023524 · ownership.xml · derivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 19,515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 19,514 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 19,515 vested on February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 19,514 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 19,515 vested on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 06:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 9,815 | $13.12 | $128,733.54 |
DisclosureSEC source: 0000950170-24-023524 · ownership.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,701 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 to $13.19, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 06:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 19,515 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-023524 · ownership.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 07:37 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 173,261 | $13.05 | $2,261,905.03 |
DisclosureSEC source: 0000950170-24-017567 · ownership.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 to $13.15, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Number of shares rounded to the nearest whole share. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 07:22 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 55,226 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-009612 · ownership.xml · derivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,226 Underlying: Ordinary Shares · 55,226 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,699 | $9.43 | $44,301.70 |
DisclosureSEC source: 0001209191-23-017157 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,262 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units reported under Table II of the Form 4 filed by the reporting person with the SEC on March 7, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 16:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,566 | $9.93 | $15,551.79 |
DisclosureSEC source: 0001209191-23-017157 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,961 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units reported under Table II of the Form 4 filed by the reporting person with the SEC on March 7, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 22,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016690 · doc4.xml · derivative · entry 7 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,152 Underlying: Ordinary Shares · 22,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 vested on March 5, 2022 and March 5, 2023, and 22,576 vesting on each of March 5, 2024 and March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 vested on March 5, 2022 and March 5, 2023, and 22,576 vesting on each of March 5, 2024 and March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 22,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016690 · doc4.xml · nonDerivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 33,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016690 · doc4.xml · derivative · entry 6 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,536 Underlying: Ordinary Shares · 33,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 11,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016690 · doc4.xml · derivative · entry 5 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 11,940 vested on each of March 4, 2021, March 4, 2022, and March 4, 2023. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 11,940 vested on each of March 4, 2021, March 4, 2022, and March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 33,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016690 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 11,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016690 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 99,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016690 · doc4.xml · derivative · entry 4 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,601 Underlying: Ordinary Shares · 99,601 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 07:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 47,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014437 · doc4.xml · derivative · entry 6 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 47,598 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. F7 · derivative.expiration_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 07:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 19,514 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014437 · doc4.xml · derivative · entry 5 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,515 Underlying: Ordinary Shares · 19,514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 19,514 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 19,515 vesting on February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 19,514 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 19,515 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 07:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 23,888 | $9.89 | $236,171.10 |
DisclosureSEC source: 0001209191-23-014437 · doc4.xml · nonDerivative · entry 4 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,499 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 07:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 47,598 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014437 · doc4.xml · nonDerivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 07:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 9,797 | $9.89 | $96,859.02 |
DisclosureSEC source: 0001209191-23-014437 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,789 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 07:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 19,514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014437 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 07:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 47,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007951 · doc4.xml · derivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,598 Underlying: Ordinary Shares · 47,598 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 11,334 | $7.37 | $83,494.18 |
DisclosureSEC source: 0001209191-22-017039 · doc4.xml · nonDerivative · entry 6 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,072 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 22,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017039 · doc4.xml · derivative · entry 10 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,728 Underlying: Ordinary Shares · 22,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F10 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 having vested on March 5, 2022 and 22,576 vesting on each of March 5, 2023, March 5, 2024 and March 5, 2025. F10 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 having vested on March 5, 2022 and 22,576 vesting on each of March 5, 2023, March 5, 2024 and March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 22,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017039 · doc4.xml · nonDerivative · entry 5 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 134,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017039 · doc4.xml · derivative · entry 9 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,048 Underlying: Ordinary Shares · 134,048 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F9 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F9 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 11,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017039 · doc4.xml · derivative · entry 8 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,940 Underlying: Ordinary Shares · 11,940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 11,940 having vested on each of March 4, 2021 and March 4, 2022, and 11,940 vesting on March 4, 2023. F8 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 11,940 having vested on each of March 4, 2021 and March 4, 2022, and 11,940 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 32,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017039 · doc4.xml · derivative · entry 7 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 32,518 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F7 · derivative.expiration_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,301 | $7.48 | $47,147.23 |
DisclosureSEC source: 0001209191-22-017039 · doc4.xml · nonDerivative · entry 4 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,830 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 11,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017039 · doc4.xml · nonDerivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 17,157 | $7.48 | $128,377.25 |
DisclosureSEC source: 0001209191-22-017039 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,191 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 16:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 32,518 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017039 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 07:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 19,514 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014468 · doc4.xml · derivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,029 Underlying: Ordinary Shares · 19,514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 19,514 having vested on each of February 28, 2021 and February 28, 2022, 19,514 vesting on February 28, 2023, and 19,515 vesting on February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 19,514 having vested on each of February 28, 2021 and February 28, 2022, 19,514 vesting on February 28, 2023, and 19,515 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 07:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 9,797 | $8.14 | $79,769.13 |
DisclosureSEC source: 0001209191-22-014468 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,830 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 07:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 19,514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-014468 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 16:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 6,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008413 · doc4.xml · derivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,568 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 6,567 having vested on each of February 9, 2020 and February 9, 2021 and 6,568 having vested on February 9, 2022. F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 6,567 having vested on each of February 9, 2020 and February 9, 2021 and 6,568 having vested on February 9, 2022. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 16:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 3,583 | $9.06 | $32,463.77 |
DisclosureSEC source: 0001209191-22-008413 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,113 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 16:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 6,568 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-008413 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 16:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 32,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008413 · doc4.xml · derivative · entry 4 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,518 Underlying: Ordinary Shares · 32,518 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. F7 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. Read SEC document |
| May 21, 2021 Filed May 25, 2021 08:41 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 40,000 | $11.01 | $440,320.00 |
DisclosureSEC source: 0001209191-21-035605 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,128 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.04, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2021 Filed May 13, 2021 07:44 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 37,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032251 · doc4.xml · derivative · entry 3 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 37,884 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021. F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 11, 2021 Filed May 13, 2021 07:44 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 19,804 | $10.22 | $202,412.72 |
DisclosureSEC source: 0001209191-21-032251 · doc4.xml · nonDerivative · entry 2 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,128 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.2206 to $10.2300, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2021 Filed May 13, 2021 07:44 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 37,884 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-032251 · doc4.xml · nonDerivative · entry 1 Drape Eric · CIK 0001790905 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.